Innate Pharma SA (IPHA) stock
IPHANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31Also trades as IPHYF
Số liệu tài chính tới năm tài chính 2025, năm kết thúc ngày Dec 31, 2025Last filing: 20-F on Apr 1, 2026Score 0/30
$1.33−0.07 (-5.34%)
Close on Nov 17, 2026Market cap $124.65MP/E –Yield –
Innate Pharma pe ratio
The price-to-earnings ratio is the share price divided by diluted earnings per share over the trailing twelve months.
Innate Pharma's pe ratio was 113.8× on Feb 28, 2020.
PE Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2020 | Feb 28, 2020 | 113.8× | −0.9 |
| 2019 | Dec 31, 2019 | 114.7× | – |
See a number that looks wrong?